Publication Name	World Journal of Clinical Pediatrics
Manuscript ID	89049
Country	Russia

Received	2023-10-19 11:35
Peer-Review Started	2023-10-19 11:36
To Make the First Decision
Return for Revision	2023-12-07 07:36
Revised	2024-01-02 18:25
Second Decision	2024-01-30 03:04
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-01-30 09:26
Articles in Press	2024-01-30 09:26
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-02-29 01:30
Publish the Manuscript Online	2024-03-07 02:39

ISSN	2219-2808 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Rheumatology
Manuscript Type	Case Control Study
Article Title	BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months case-control study
Manuscript Source	Invited Manuscript
All Author List	Elvira Kalashnikova, Eugenia Isupova, Ekaterina Gaidar, Lyubov Sorokina, Maria Kaneva, Vera Masalova, Margarita Dubko, Tatiana Kornishina, Natalia Lubimova, Ekaterina Kuchinskaya, Irina Chikova, Rinat Raupov, Olga Kalashnikova and Mikhail Kostik
ORCID	Author(s) ORCID Number Elvira Kalashnikova http://orcid.org/0000-0002-4932-0588 Eugenia Isupova http://orcid.org/0000-0002-0911-7817 Ekaterina Gaidar http://orcid.org/0000-0002-0971-2018 Lyubov Sorokina http://orcid.org/0000–0002–9710–9277 Maria Kaneva http://orcid.org/0000-0003-4325-0125 Vera Masalova http://orcid.org/0000-0002-3703-4920 Margarita Dubko http://orcid.org/0000-0002-6834-1413 Tatiana Kornishina http://orcid.org/0000-0002-6238-4121 Natalia Lubimova http://orcid.org/0000-0002-5782-8373 Ekaterina Kuchinskaya http://orcid.org/0000-0002-1383-3373 Irina Chikova http://orcid.org/0000-0003-4636-5825 Rinat Raupov http://orcid.org/0000-0001-7749-6663 Olga Kalashnikova http://orcid.org/0000-0002-8683-4270 Mikhail Kostik http://orcid.org/0000-0002-1180-8086
Funding Agency and Grant Number	Funding Agency Grant Number Ministry of Science and Higher Education of the Russian Federation 075-15-2022-301 Russian Science Foundation 22-45-08004
Corresponding Author	Mikhail Kostik, MD, PhD, Professor, Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Lytovskaya 2, Saint-Petersburg 194100, Russia. kost-mikhail@yandex.ru
Key Words	Systemic lupus erythematosus; Children; Rituximab; Anti-B-cell therapy; Glucocorticosteroids
Core Tip	Rituximab (RTX), known as an anti-B-cells agent, is actively discussed as one of the main drugs for severe systemic lupus erythematosus. Various studies have been conducted to evaluate its effectiveness, but their results are ambiguous. We show the benefits of RTX above the standard-of-care treatment in children.
Publish Date	2024-03-07 02:39
Citation	Kalashnikova E, Isupova E, Gaidar E, Sorokina L, Kaneva M, Masalova V, Dubko M, Kornishina T, Lubimova N, Kuchinskaya E, Chikova I, Raupov R, Kalashnikova O, Kostik M. BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months case-control study. World J Clin Pediatr 2024; 13(1): 89049
URL	https://www.wjgnet.com/2219-2808/full/v13/i1/89049.htm
DOI	https://dx.doi.org/10.5409/wjcp.v13.i1.89049

Full Article (PDF)	WJCP-13-89049-with-cover.pdf
Full Article (Word)	89049.docx
STROBE Statement	89049-STROBE statement.pdf
Manuscript File	89049_Auto_Edited-LJH-YJP.docx
Answering Reviewers	89049-Answering reviewers.pdf
Audio Core Tip	89049-Audio core tip.m4a
Biostatistics Review Certificate	89049-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	89049-Conflict-of-interest statement.pdf
Copyright License Agreement	89049-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	89049-Grant application form(s).pdf
Signed Informed Consent Form(s) or Document(s)	89049-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	89049-Institutional review board statement.pdf
Peer-review Report	89049-Peer-review(s).pdf
Scientific Misconduct Check	89049-Bing-Liu JH-2.png
Scientific Misconduct Check	89049-CrossCheck.png
Scientific Editor Work List	89049-Scientific editor work list.pdf
CrossCheck Report	89049-CrossCheck report.pdf